AMERICAN SHARED HOSPITAL SERVICES (AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, Inc. regarding Mevion Medical Systems' receipt of FDA 510(k) clearance for its MEVION S250 Proton Therapy System.
"The Mevion team has created a truly revolutionary medical therapy device. Revolutionary in the sense that this machine combines the elements of a superconducting synchrocyclotron mounted on a gantry that is less expensive than all other proton therapy devices, using accelerator technology that has been proven to be reliable and simple for the user," said AMS Chairman and Chief Executive Officer Ernest A. Bates, M.D.
"This is an exciting day for Mevion, for AMS, and for cancer patients and clinicians worldwide. The MEVION S250 significantly reduces the cost, size and complexity of proton technology, and promises to bring accessibility, affordability and practicality to this innovative therapy. With FDA 510(k) clearance for the MEVION S250 now in hand, we expect AMS' proton therapy business to accelerate, both the projects we have already announced as well as additional projects that have awaited the FDA's positive decision," said Craig K. Tagawa, Chief Operating Officer of AMS.
AMS owns approximately 1% of Mevion, and is developing proton therapy centers in Orlando, Boston and Long Beach, California which are expected to employ the MEVION S250 proton therapy device:Mevion Medical Systems Announces FDA 510(k) Clearance for the MEVION S250 Proton Therapy System MEVION S250 patented technology significantly reduces the cost of implementing and operating proton therapy centers. LITTLETON, MA., June 11, 2012 -- Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced today that it has received FDA 510(k) clearance for its MEVION S250 Proton Therapy System. The MEVION S250 is a first-of-its-kind proton/therapy system that provides the same precise, non-invasive treatment advantages and capabilities of complex, large, and costly proton therapy systems but with higher patient throughput, a significantly reduced footprint, improved reliability, and lower implementation and operational costs. The MEVION S250 delivers precise and intense proton beams that physicians can use to treat tumors and lesions or any other condition where radiotherapy is indicated.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV